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Abstract: Fluid shear stress stimulates endothelial nitric oxide synthase (eNOS) activation and nitric
oxide (NO) production through multiple kinases, including protein kinase A (PKA), AMP-activated
protein kinase (AMPK), AKT and Ca2+/calmodulin-dependent protein kinase II (CaMKII).
Membrane-associated guanylate kinase (MAGUK) with inverted domain structure-1 (MAGI1) is an
adaptor protein that stabilizes epithelial and endothelial cell-cell contacts. The aim of this study was
to assess the unknown role of endothelial cell MAGI1 in response to fluid shear stress. We show
constitutive expression and co-localization of MAGI1 with vascular endothelial cadherin (VE-cadherin)
in endothelial cells at cellular junctions under static and laminar flow conditions. Fluid shear stress
increases MAGI1 expression. MAGI1 silencing perturbed flow-dependent responses, specifically,
Krüppel-like factor 4 (KLF4) expression, endothelial cell alignment, eNOS phosphorylation and NO
production. MAGI1 overexpression had opposite effects and induced phosphorylation of PKA, AMPK,
and CAMKII. Pharmacological inhibition of PKA and AMPK prevented MAGI1-mediated eNOS
phosphorylation. Consistently, MAGI1 silencing and PKA inhibition suppressed the flow-induced
NO production. Endothelial cell-specific transgenic expression of MAGI1 induced PKA and
eNOS phosphorylation in vivo and increased NO production ex vivo in isolated endothelial cells.
In conclusion, we have identified endothelial cell MAGI1 as a previously unrecognized mediator of
fluid shear stress-induced and PKA/AMPK dependent eNOS activation and NO production.
Keywords: fluid shear stress; MAGI1; signal transduction; eNOS; endothelial cell; nitric oxide/NO
1. Introduction
Nitric oxide (NO) is a key regulator of homeostasis and adaptive responses of the vascular
system [1]. NO is generated from L-arginine and molecular oxygen by a family of enzymes called
nitric oxide synthases (NOS). There are three mammalian NOS isoforms: neuronal NOS (nNOS,
NOS I), inducible NOS (iNOS, NOS II) and endothelial NOS (eNOS NOS III) [1]. They consist of
an N-terminal oxygenase domain with binding sites for heme, l-arginine and tetrahydrobiopterin;
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a central calmodulin-binding region and a C-terminal reductase domain containing binding sites for
nicotinamide adenine dinucleotide phosphate, flavin adenine dinucleotide and mononucleotide [2].
The main NOS isoform expressed in endothelial cells is eNOS, which acts as an important regulator of
essential vascular functions including vascular tone, angiogenesis, atheroprotection, anti-inflammatory
and anti-thrombotic activities [3,4]. A reduction of endothelial NO production is associated with
endothelial dysfunctions as observed in hypertension, diabetes and atherosclerosis [5,6]. Regulation of
eNOS is complex and occurs at transcriptional, post-transcriptional and post-translational levels [7,8].
Fluid shear stress and cyclic stretch are important inducers of eNOS expression and activity [9].
A main mechanism of regulation of eNOS activity is phosphorylation [4]. Several tyrosine (Tyr),
serine (Ser) and threonine (Thr) residues are phosphorylated on eNOS. Ser1177 phosphorylation is
critical for its activation and function [10] and can be mediated by AKT [11], AMP-activated protein
kinase (AMPK) [12], Ca2+/calmodulin-dependent protein kinase II (CaMKII) [13] and protein kinase
A (PKA) [14]. AKT and PKA were shown to be the main mediators of Ser1177 phosphorylation in
response to shear stress. The roles of other phosphorylation sites, in particular Tyr8, Ser114, Ser633 and
Tyr657, are still under investigation [1,4].
MAGI1 (MAGUK with inverted domain structure-1), together with MAGI2 and MAGI3, is a
member of the MAGUK family of proteins. It consists of six PDZ (post-synaptic density protein 95
(PSD-95)-Drosophila disc large tumour suppressor (Dlg1)-zona occludens 1 (ZO-1)) domains, a single
catalytically inactive guanylate kinase domain and two WW (tryptophan-tryptophan) domains [15].
MAGI1 exerts a scaffolding function supporting the assembly of multiprotein complexes at the inner
surface of the plasma membrane, particularly at regions of cell-cell contacts thereby stabilizing cell-cell
adhesions [16]. In epithelial cells, MAGI1 localizes at cellular junctions and recruits the tumour
suppressor PTEN (phosphatase and tensin homolog) to stabilize adherens and tight junctions and to
suppress cell motility, the latter, at least in part, by competing with TRIP6 (thyroid receptor-interacting
protein 6) binding to PTEN [16,17].
Little is known about the role of MAGI1 in endothelial cell functions particularly its response
to shear stress. MAGI1 was shown to mediate Rap1 activation and enhancement of VE-cadherin-
dependent endothelial cell-cell adhesion [18]. Endothelial cell-selective adhesion molecule (ESAM)
binds MAGI1 and recruits it to cell-cell contacts to strengthen adhesions [19]. Here, we report
MAGI1 as a novel fluid shear stress-induced transcript/protein in endothelial cells that regulates eNOS
phosphorylation and NO production through PKA/AMPK-dependent phosphorylation at Ser1177.
2. Materials and Methods
2.1. Reagents
Dulbecco PBS (DPBS), Ca2+-free PBS, medium-199 (M199), DMEM, penicillin/streptomycin, G418
and trypsin were purchased from Invitrogen Life Technologies (Basel, Switzerland). KAPA SYBR
FAST Universal 2× quantitative PCR Master Mix kit was from Kapa Biosystems (Boston, MA, USA).
Foetal bovine serum (FBS) was from Eurobio (Les Ulis, France). Luminata Western HRP substrate was
purchased from Millipore (Boston, MA, USA). DAPI (4,6-diamidino-2-phenylindole), BSA, bovine
gelatine, plasma fibronectin, collagen-I, PFA, crystal violet, SigmaFAST protease inhibitors, thrombin
and puromycin were purchased from Sigma-Aldrich (Buchs, Switzerland). Human VEGF-A 165 was
from R and D Systems (Minneapolis, MN, USA). Bradford and RC-DC assays for protein concentration
measurement were from Bio-Rad (Richmond, CA, USA). PageRuler prestained and Spectra multicolour
protein ladder were from Thermo Fisher Scientific (Reinach, Switzerland). Diaminofluorescein-2
Diacetate (DAF-2DA) was from Cell Technology Inc. (San Jose, CA, USA), Cell Meter™ Fluorimetric
Intracellular Nitric Oxide (NO) Activity Assay Kit *Red Fluorescence Optimized for Flow Cytometry
(cat. no. 16356) is from AAT Bioquest, Inc. (Sunnyvale, CA, USA). AKT inhibitor MK-2206, CAMKII
inhibitor KN-93 phosphate and AMPK specific inhibitor dorsomorphin (compound C) were purchased
from Selleck Chemicals (Huston, TX, USA). The PKA inhibitor, H-89 was purchased from Cell Signalling
Technology (Danvers, MA, USA).
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2.2. Antibodies
Antibodies to MAGI1 (rabbit polyclonal (cat. no. M5691) Prestige, cat. no. HPA031853, mouse
monoclonal antibody, cat. no. WH0009223M3), actin (cat. no. A3853) and GAPDH (cat. no. G9545)
were from Sigma-Aldrich (Buchs, Switzerland). Anti-CAMKII (phospho Thr286, cat. no. 3361 and total,
cat. no. 3362), anti-PKA (phospho Thr197, cat. no. 4781 and total, cat. no. 4782), anti-AKT (phospho,
Ser473, cat. no. 9271 and total cat. no. 9272), anti-KLF4 (cat. no. 4038) and anti-eNOS (phospho
Ser1177 cat. no. 9572 and total, cat. no. 9571), anti-AMPKα (phospho Thr172, cat. no. 2535, total cat.
no. 2532) antibodies were from Cell Signalling Technology (Danvers, MA, USA). Anti-VE-cadherin
antibody (cat. no. 605252) was from BD Biosciences (Allschwill, Switzerland). Phalloidin–FITC
(cat. no. P5282) was from Sigma-Aldrich (Buchs, Switzerland). Goat anti-mouse IgG–HRP (cat.
no. P0447) and goat anti-rabbit IgG-HRP (cat. no. P0448) were from DAKO (Glostrup, Denmark).
Fluorochrome-conjugated anti-mouse (cat. no. A10037) and anti-rabbit (cat. no. A21206) antibodies
for immunofluorescence were purchased from Invitrogen, Thermo Fisher Scientific (Waltham, MA,
USA). Florescent secondary antibodies for Western blotting were: goat anti-mouse IgG or anti-rabbit
IgG Dylight 680 or 800 from Thermo Fisher Scientific (Waltham, MA, USA).
2.3. Cell Culture
HUVEC (human umbilical vein endothelial cells) were prepared from umbilical cords and cultured
as previously described [20] and used between passage 3 and 7. HEK293T cells were grown in DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin. Use of HUVEC was approved by the
both ethic committees of Canton Vaud, Switzerland and WWU–Muenster (2009-537-f-S). HUVEC
stimulation with: VEGF: 100 ng/mL for 24 h; thrombin: 10 U/mL for 30 min.
2.4. Immunofluorescence Staining and Confocal Microscopy
HUVECs were seeded on gelatin-coated glass coverslips in a 12-well plate or IBIDI slides (ibidi,
Martinsried, Germany) and cultured to confluency. Upon treatment, cells were washed with DPBS,
fixed in PFA for 5 min at room temperature, blocked and permeabilized (0.5% BSA, 5% donkey serum,
0.1% TritonX-100 in DPBS) for 30 min. Cells were incubated with primary antibodies overnight at
4 ◦C, washed with DPBS 4–5 times and incubated with relevant fluorescent-conjugated secondary
antibodies. DAPI (4,6-diamidino-2-phenylindole) was used to counterstain nuclei. The stained cells
were mounted with ‘Prolong’ antifade mounting medium (Molecular Probes (Basel, Switzerland) and
imaged using a Leica TCS SP5 DMI6000 confocal microscope (Leica Microsystems, Wetzlar, Germany).
2.5. Plasmids, Lentivirus Production and Transduction
For gene silencing experiments, the pCMVGIN- ZEO lentiviral shRNAmir expressing system
was purchased from Open Biosystems (Huntsville, AL, USA). For the shRNAmir sequences directed
against the human MAGI1, three different clones were used: V2LHS-36239 (SH1), V2LHS-36236
(SH2) and V3LHS_346390 (SH4). SH1 and SH2 shRNAmir sequences and a non-silencing control
shRNAmir sequence that contains no homology to known mammalian genes, were subcloned into
the pCMV-GIN-ZEO lentiviral system. SH4 was used in the original vector. Human MAGI1 cDNA
was kindly provided by Dr Y. Hata (Dept. Medical Biochemistry, Graduate School of Medicine, Tokyo
Medical and Dental University. Tokyo, Japan) and sub-cloned into pRRLSIN.cPPT.PGK/GFP.WPRE
lentiviral vector under the control of the PGK promoter (= pSD44 plasmid). Cell cultures were
transduced by over-night incubation at 37 ◦C in virus-containing media in the presence of 8 µg/mL
polybrene (Sigma-Aldrich, Buchs, Switzerland). Selection was started on bulk cultures 48 h after
transduction using 2 µg/mL Puromycin (Sigma-Aldrich) for pSD44-MAGI1-cDNA construct or
250 µg/mL G418 (Calibiochem, CA, USA) for pCMV-GIN-ZEO constructs.
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2.6. Fluid Shear Stress Experiments
Ibidi parallel plate flow system- The protocol was based on the original method [21]. ‘Ibitreat’ slides
were coated with 1% gelatin for 4 h at 37 ◦C. Two types of channel slides were used: µ-Slide I 0.4 luer
and µ-Slide I 0.6 luer for flow applications and high channel (0.8 luer) for static conditions. For µ-Slide
I 0.4 luer (100 µL channel volume); 1 × 106 cells/mL were plated while 1.6 × 106 cells/mL were plated
in µ-Slide I 0.6 luer (150 µL channel volume) to obtain a 100% confluent cell layer after 24 h. Confluent
slides were placed under flow using ibidi pump system (ibidi, Martinsried, Germany) at 10 dy/cm2
steady, unidirectional shear stress for 24 h.
Orbital-shaker system- The protocol modified form the original method [20]. 6-well plates were
coated with 1% gelatin, 3 µg/mL fibronectin or 1 µg/mL collagen for 4 h. HUVEC were plated and
cultured to confluence. Confluent plates were fixed on a horizontal orbital shaker (Vibromix 314 EVT
orbital shaker, Tehtnica, Železniki, Slovenia) with an orbit of 38 mm generating a modelled oscillatory
shear stress of 10–13 dyn/cm2 at the periphery of the plate as previously reported using the finite
element method [20]. After 24 h, the cells at the central half of the diameter (exposed to a modelled shear
stress < 5 dyn/cm2) were removed with cell scraper, leaving the periphery of the cultures intact. Cells
were imaged using a Leica AF6000 microscope (Leica Microsystems, Wetzlar, Germany). For Western
blotting, RIPA lysis buffer was added to the wells and processed as described [22].
Cone-and-plate system- Experiments were conducted using the fully automated BioTechFlow system
(BTF), (MOS Technologies, Telgte, Germany) as described elsewhere [23,24]. The chamber plates
were coated with 0.5% crosslinked gelatine as described elsewhere (25) before cells were seeded at
30,000 cells/cm2 in endothelial cell growth medium (Promocell, Heidelberg, Germany) under 5% CO2,
50 U/mL/50 µg/mL of Penicillin-Streptomycin, 3% Polyvinyl-pyrrolidone (MW: 360 kDa) was added to
increase the dynamic viscosity. Diameter of the cone was 28 mm and the cone angle was 2.5◦. Cells
were exposed to 10 dyn/cm2 shear stress for 24 h. Phase-contrast microscopy is integrated to the system
allowing real-time observation of endothelial cells.
2.7. Real-Time PCR
Total RNA was extraction, reverse transcription and real-time PCR were done as reported
earlier [22]. Ct values of target genes normalized upon the Ct values of housekeeping genes (GAPDH
for HUVEC and mouse 36B4 for mouse lung endothelial cells) were calculated between samples
and the expression level was compared. All real time PCR reactions were done in triplicate, and
the data from one of three independent experiments are shown. Primer sequences used were
as follows: MAGI1 (NM_004742.2) forward: 5′-TTCAAGCCGTCAGACAAG-3′, MAGI1 reverse:
5′-ATGGCCGTAAAGGTTATCCC-3′; GAPDH forward: 5′-GGACCTGACCTGCCGTCTAG-3′;
GAPDH reverse: 5′-CCACCACCCTGTTGCTGTAG-3′, Mouse 36B4: Forward: 5′-GTGTGTCTGCAGA
TCGGGTAC-3′. Reverse: 5′-CAGATGGATCAGCCAGGAAG-3′.
2.8. Western Blotting
SDS PAGE and Western blotting were performed following standard procedures as described [22].
Each sample (=lane) consists of the pool of three independent culture wells of a six-well plate.
Detection was performed by chemo luminescence using Luminata Substrate or by Li-cor Odyssey CLx
(Lincoln, NE, USA) using florescent secondary antibodies diluted in 1% BSA and blocking buffer for
fluorescent antibody (Odyssey blocking buffer (TBS) from Li-cor). For quantification Western blot
protein densitometry data were quantified with ImageJ and Alpha View software (Biotechne, San Jose,
US) based on multiple experiments.
2.9. NO Measurement
The Cell Meter™ Fluorimetric Intracellular Nitric oxide (NO) Activity Assay Kit- Trypsinised HUVECs
were resuspended in medium at 5 × 105 cells/mL and incubated with 2 µL of 500× Nitrixyte™ Red
(Component A) for 30 min at 37 ◦C. After washing in PBS, the cells were monitored for the fluorescence
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intensity at the FL4 channel (Ex/Em = 630/660 nm) using a FACSCalibur flow cytometer (BD, Mountain
View, CA). The negative controls were cells without the Nitrixyte™ Red probe added. The data
obtained were analysed by FlowJo software (Ashland, OR, USA).
The DAF-2DA fluorescence labelling technique- HUVEC cultures at confluence were washed with
PBS and incubated with 5 µmol/L of DAF-2DA for 30 min. After incubation, cells were washed twice
with PBS, and fixed with 2.5% PFA. Pictures were taken with an inverted fluorescent microscope (Leica
DMI6000B, Leica Microsystems, Wetzlar, Germany) and intensity values were obtained with emission
at 515 nm with a VICTOR X3 spectrophotometer from PerkinElmer Inc. (Waltham, MA, USA).
2.10. Kinase Inhibition Assays
Confluent HUVECs were serum-starved for 2 h in M199 medium with 0.5% FCS except for
CaMKII inhibition. Inhibitors were dissolved in DMSO at 10 to 50 mM and diluted in M199 medium
immediately before use. Cells were then treated as following: MK-2206, 1 µM, for 1 h; H-89, 20 µM,
30 min; Dorsomorphin, 10 µM for 2 h no serum starvation; KN-93, 20 µM, 24 h, no serum starvation.
2.11. Animal Studies
The human MAGI1 cDNA (NM_004742.2, 3770bp) was inserted into the pTetOS responder
construct to generate transgenic animals. Driver and responder transgenic animals were bred to
generate bigenic mice. Offspring was genotyped to generate wild type, single (ST, tetOS:MAGI1
and VEC:tTA) and double transgenics (DT, VEC:tTA:: tetOS:MAGI1) mice. In the absence of
doxycycline, mice constitutively overexpress transgenic MAGI1 in endothelial cells while in the
presence of doxycycline transgenic expression of MAGI1 is silenced. Doxycycline treatment involved
the addition of 100 µg/mL of doxycycline (cat. no. D9891, Sigma-Aldrich)]/5% sucrose in the drinking
water and was changed at least twice per week. Animals were euthanized by CO2 inhalation
followed by neck dislocation. Animal experiments were approved by the Cantonal Office in Fribourg
(Ruegg_2014_26_FR) and performed according to Swiss regulations and to the guidelines from Directive
2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
We used both male and female mice between 6 and 10 weeks of age. The following primers were
used for genotyping the mice: VEC_forward: 5′GACGCCTTAGCCATTGAGAT 3′, VEC_reverse:
5′CAGTAG TAG GTGTTTCCCTTTCTT 3′, MAGI1_forward: 5′ TCATTCCTGGGCATGAGTCCT 3′,
MAGI1_reverse: 5′GCCAGGGAAGGAAGGATTGT3′.
2.12. Isolation of Mouse Lung Endothelial Cells
Lungs from freshly sacrificed mice were cut and digested in 1% Collagenase and 2.5 µg/mL of
DNase I, both from Sigma-Aldrich (Buchs, Switzerland) for 45 min at 37 ◦C. After passing through
70 µm filters, cells were washed once in PBS with 2 mM EDTA and twice in PBS only. Cells were
resuspended in DMEM:F12 supplemented with 2% FBS, 1% penicillin/streptomycin, 20 ng/mL EGF
and 10 µg/mL insulin and plated on Collagen I (10 µg/mL) coated plates.
2.13. Immunohistochemical Staining
Tissue sections were heated in Tris-EDTA buffer to retrieve antigen epitopes, blocked by 10%
normal goat serum and Avidin/Biotin blocking reagent (Vector Laboratories, Burlingame, CA, USA)
and stained with the following primary antibodies at 4 ◦C overnight: anti-MAGI1 (Sigma-Aldrich,
Buchs, Switzerland, cat. no. HPA031853), P-eNOS (Ser1177, Cell Signaling, Danvers, MA, USA;
cat. no. 9571S) and total eNOS (Cell Signaling, Danvers, MA, USA; cat. no. 9572S). Sections were
incubated with biotinylated secondary antibodies followed by Vectastain ABC Kit (Vector Laboratories,
Burlingame, CA, USA) with DAB peroxidase substrate (Sigma-Aldrich). Sections were counterstained
with haematoxylin before mounting.
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2.14. Statistical Analysis
Statistical analysis on data expressed as the mean ± SEM was performed on the basis of unpaired
t-test or two-way ANOVA, followed by Sidak’s multiple comparison test, where necessary using
GraphPad Prism software (San Diego, CA, USA). A value of p < 0.05 was considered to be significant.
*p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. N, repeated experiments; n, replicates per experiment.
3. Results
3.1. MAGI1 Localizes at Endothelial Cell-Cell Contacts and its Expression is Induced by Fluid Shear Stress
The role of MAGI1 in vascular biology and its response to fluid shear stress are largely unknown.
To address this question, we first monitored MAGI1 expression and localization in confluent human
umbilical vein endothelial cells (HUVEC) by confocal immunofluorescence microscopy. Under static
conditions (0.5 dyn/cm2), MAGI1 localized at cell-cell contacts as continuous staining in co-localization
with VE-cadherin (Figure 1A), consistent with previous reports [18]. Upon 24 h exposure to fluid
shear stress (10 dyn/cm2) in the cone-and-plate BioTechFlow-system (BTF) [25], we observed HUVEC
alignment and a linear but more interdigitated VE-cadherin localization, as a sign of response to flow
consistent with previous reports [25,26] and MAGI1 co-localized with VE-cadherin at cell-cell junctions
(Figure 1A, Supplemental Figure 1A).
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(A) Confocal laser microscopy of MAGI1 and VE-cadherin-stained HUVEC confluent cultures under
static conditions (0.5 dyn/cm2) and after enhanced fluid shear stress of 10 dyn/cm2 for 24 h using the
BioTechFlow system (BTF). MAGI1 co-localizes with VE-cadherin under static and flow conditions.
Arrows: direction of flow. N = 5. Scale bar = 25 µm. (B) HUVEC cultured under static conditions or
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exposed to 10 dyn/cm2 fluid shear stress (flow) in the parallel plates (ibidi), orbital shaker (OS) and
cone-and-plate (BTF) systems were analysed by Western blotting for MAGI1 protein levels. Fluid
shear stress induced MAGI1 protein in the three models. N = 3–5. (C) HUVEC cultured under static
conditions (0) or exposed to 10 dyn/cm2 fluid shear stress in the orbital shaker (OS) systems for the
indicated time were analysed for MAGI1 protein levels by Western blotting. N = 2, duplicate samples
each condition. Maximal MAGI1 induction is reached at 24 h. Beta actin blotting are shown as loading
controls. Relative band quantifications by densitometry of multiple experiments are shown next to the
blots. (D) MAGI1 mRNA levels in HUVEC under static and fluid shear stress conditions in the OS
and BTF models measured by real time RT-PCR. Fluid shear stress induces MAGI1 mRNA expression.
N = 3, in triplicate conditions. * p < 0.05; ** p < 0.01.
Next, we monitored the effect of shear stress (10 dyn/cm2) on MAGI1 expression in the BTF
system and two additional flow systems: the orbital shaker [20] and the parallel plates (ibidi) [27]
models. As in the BTF model, 24 h fluid shear stress in orbital shaker and parallel plates system also
induced HUVEC alignment (Figure S1A). Interestingly, shear stress induced an increase in levels of
MAGI1 in the three systems (Figure 1B). Increased protein levels were detected as soon as 3 h after
flow start and were maximal at 24 h (Figure 1C). Flow also increased MAGI1 mRNA levels, indicative
of transcriptional regulation (Figure 1D).
The data demonstrate that MAGI1 is present at endothelial cell junctions under both static
and physiological shear stress conditions and that shear stress induces MAGI1 mRNA and protein
expression. For subsequent biochemical studies, we adopted the orbital shaker model as it allows
treating larger amounts of cells in multiple parallel conditions.
3.2. MAGI1 Facilitates Endothelial Cell Alignment and KLF4 Expression in Response to Fluid Shear Stress
As MAGI1 co-localizes with VE-cadherin at cell-cell contacts and VE-cadherin was indicated
to be a part of a junctional mechanosensory complex together with PECAM-1 and VEGFR-2 [28],
we hypothesized that MAGI1 itself could participate in the mechanotransduction response to fluid
shear stress. To test this hypothesis, we monitored the effect of modulating MAGI1 levels on flow
induced HUVEC alignment [29]. HUVEC with overexpressed or silenced MAGI1 were exposed to
fluid shear stress (10 dyn/cm2) for 24 h. MAGI1 overexpression facilitated HUVEC alignment while
MAGI1 silencing interfered with it, compared to control cells (Figure 2A). Next, we monitored the
effect of MAGI modulation on the expression of Krüppel-like factor 4 (KLF4), a transcription factor
regulated by flow that mediates essential vascular functions in response to flow [30]. MAGI1 silencing
prevented flow-induced KLF4 expression (Figure 2B), while MAGI1 overexpression increased KLF4
expression in the absence of flow (Figure 2C).
HUVEC stimulation with vascular endothelial growth factors (VEGF) or thrombin, two
physiological activators of endothelial cells, did not induce MAGI1 expression, suggesting that
the observed induction is a rather specific response to shear stress.
These results demonstrated that endothelial cell MAGI1 is induced by fluid shear stress and is
involved in mediating endothelial cell response to it.
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Figure 2. MAGI1 mediates endothelial cell alignment and KLF4 expression upon exposure to fluid
shear stress. (A) Control HUVEC (NS), HUVEC with silenced (SH) or overexpressed (OE) MAGI1 were
exposed to laminar shear stress (10 dyn/cm2) in the orbital shaker model (OS) for 24 h. MAGI1 SH
perturbs, while MAGI1 OE facilitates alignment. Arrows: direction of flow. N = 5. Scale bar = 20 µm.
(B) Western blotting analysis of control (NS) and MAGI1 silenced (SH1 and SH2) HUVEC under static
and orbital flow conditions (OS) for 24 h. MAGI1 silencing prevents KLF4 induction under shear stress.
N = 3. (C) Western blotting analysis of control (Mock) and MAGI1-overexpressing (OE) HUVEC under
static conditions. N = 3. (D) Western blotting analysis of cultured control HUVEC (Ctrl) or HUVEC
exposed to VEGF (100 ng/mL for 24 h) and thrombin (10 U/mL for 30 min). Beta actin or GAPDH are
shown as loading controls. Relative band quantifications by densitometry of multiple experi ents are
shown next to the blots. * p < 0.05; ** p < 0.01; *** p < 0.001.
3.3. MAGI1 Promotes eNOS Phosphorylation and NO Production in Response to Fluid Shear Stress
Fluid shear stress is a potent regulator of eNOS function and NO production [31]. To test the role
of MAGI1 in shear stress-mediated eNOS activation, we monitored eNOS phosphorylation at Ser1177,
a phosphorylation site associated with increased eNOS activity [1,4] in MAGI1-silenced HUVEC or
control HUVEC in response to flow (10 dyn/cm2 for 24 h). In non-silenced HUVEC, we observed
a robust induction of eNOS Ser1177 phosphorylation in response to flow while in MAGI1-silenced
HUVEC, eNOS Ser1177 phosphorylation was strongly reduced (Figure 3A). Conversely, MAGI1
overexpression increased eNOS Ser1177 phosphorylation in the absence of flow (Figure 3B). In time
course experiments, we observed an initi l decrease of eNOS Ser1177 phos h rylati upon exposure
to flow in non-silenced HUVEC, followed by an incre se to maximal lev ls at 24 h. MAGI1 silencing
pr vented the flow-induced phosph rylation a later time points (6 and 24 h) (Figure 3C, Figure S1B).
Consistent with these observations, MAGI1 overexpression enhanced NO production un er both static
and flow conditions compared to mock and non-silencing c trols, while MAGI1 silencing reduced
NO pro uction in response to flow (Figure 3D).
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Figure 3. MAGI1 promotes eNOS phosphorylation. (A) Control (NS) and MAGI1-silenced (SH) HUVEC
under static or flow (10 dyn/cm2, OS) conditions for 24 h were analysed by Western blotting for eNOS
Ser1177 phosphorylation, total eNOS and MAGI1. No. of repetitions = 2. (B) Western blotting analysis
of eNOS Ser1177 phosphorylation total eNOS and MAGI1 in control (Mock) and MAGI1-overexpressing
(OE) HUVEC under static conditions. MAGI is required for and mediates eNOS phosphorylation. N =
3. Beta actin is shown as loading control. Relative band quantifications by densitometry of multiple
experiments are shown next to the blots. (C) Non-silenced (NS) or MAGI1 silenced (SH4) HUVEC were
cultured under static conditions (0) or exposed to 10 dyn/cm2 fluid shear stress in the orbital shaker
(OS) systems for the indicated time and analysed for phosphorylated (Ser1177) and total eNOS levels by
Western blotting. MAGI silencing reduces sustained flow-induced eNOS phosphorylation. (D) Control
HUVEC (Mock and NS), HUVEC with silenced (SH) or overexpressed MAGI1 (OE) under static of flow
(10 dyn/cm2, 24 h) conditions were monitored for NO production. N = 3, triplicate conditions each.
** p < 0.01; *** p < 0.001; ns, non-significant.
These results indicated that MAGI1 mediates shear stress-induced sustained eNOS activation and
NO production.
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3.4. MAGI1-Induced eNOS Phosphorylation at Ser1177 is Independent of AKT and CaMKII
MAGI1 guanylate kinase domain has no enzymatic activity, a feature shared with all MAGUK
proteins [15], implying that MAGI1 phosphorylates eNOS indirectly through other kinases. Four
kinases activate eNOS through phosphorylation at Ser1177: AKT, CaMKII, PKA and AMPK [1,4]. AKT
was a prime candidate as it phosphorylates eNOS in response to shear stress [32] and the tumour
suppressor protein PTEN, a negative regulator of AKT, binds to MAGI1 [33]. MAGI1 silencing and
overexpression, however, had no impact on AKT Ser473 phosphorylation (Supplemental Figure 2A).
Also, the AKT inhibitor MK2206, while effectively suppressing basal AKT Ser473 phosphorylation, had
no effect on eNOS Ser1177 phosphorylation induced by MAGI1 overexpression (Figure S2B).
Next we looked at CaMKII, an alternative candidate as MAGI1 interacts with α-actinin-4 [34]
and α-actinin-4 itself contributes to CaMKII activation, and binds to and regulates eNOS activity [35,
36]. To this end, we monitored the effect of the CaMKII kinase inhibitor KN-93 on eNOS Ser1177
phosphorylation in MAGI1 control and overexpressing HUVEC. MAGI1 overexpression induced
a small increase in CAMKII phosphorylation and KN-93 treatment effectively inhibited CAMKII
phosphorylation but did not impact eNOS Ser1177 phosphorylation (Figure S3A).
From these results, we concluded that AKT and CaMKII are not significantly implicated in
MAGI1-induced eNOS Ser1177 phosphorylation.
3.5. AMPK and PKA Mediate MAGI1-Induced eNOS Ser1177 Phosphorylation
AMPK was recently shown to regulate eNOS Ser1177 phosphorylation independently of AKT [37].
Thus, we examined the effect of MAGI1 on AMPK phosphorylation and whether inhibition of
AMPK suppressed eNOS phosphorylation. MAGI1 overexpression induced AMPK and eNOS Ser1177
phosphorylation while the AMPK inhibitor dorsomorphin inhibited both of these phosphorylations
(Figure 4A). PKA also regulates eNOS phosphorylation at Ser1177 in response to shear stress,
independently of AKT [38]. MAGI1-overexpression increased PKA phosphorylation and treatment with
the PKA inhibitor H89 inhibited PKA and eNOS phosphorylation in control and MAGI1-overexpressing
HUVEC (Figure 4B). Time-course experiments showed that eNOS phosphorylation paralleled PKA
phosphorylation (Figure 4C). In time course experiments, we observed a clear induction of sustained
PKA phosphorylation in response to flow in NS HUVEC, while phosphorylation was blunted in
MAGI1-silenced HUVEC (Figure 4D, Figure S3B). Consistent with these results, treatment with
H89 suppressed NO production in wild type HUVEC under static and fluid shear stress conditions
(Figure 4E), confirming the role of PKA in regulating eNOS activity independent of AKT.
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Figure 4. AMPK and PKA mediate MAGI1-induced eNOS phosphorylation. (A) Control (Mock) and
MAGI1-overexpressing (OE) HUVEC treated with the AMPK inhibitor dorsomorphin (DM, +) or
DMSO vehicle control (−), were analysed by Western blotting for phosphorylated AMPK (Thr286),
total AMPK, phosphorylated eNOS (Ser1177) and total eNOS. N = 3. AMPK mediate MAGI1-induced
eNOS phosphorylation. (B) Western blotting analysis of phosphorylated PKA (Thr197), total PKA,
phosphorylated eNOS and total eNOS in control (Mock) and MAGI1 overexpressing (OE) HUVEC in the
presence of absence of the PKA inhibitor H-89. PKA mediates MAGI1-induced eNOS phosphorylation.
N = 3. Beta actin is shown as loading control. Relative band quantifications by densitometry of
multiple experiments is shown next to the blots. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, non-significant.
(C) HUVEC cultured under static conditions (0) or exposed to 10 dyn/cm2 fluid shear stress in the
orbital shaker (OS) systems for the indicated time were analysed for phosphorylated eNOS (Ser1177),
total eNOS, phosphorylated PKA (Thr197) and total PKA levels by Western blotting. (D) HUVEC
non-silenced (NS) or silenced (SH4) for MAGI1 were cultured under static conditions or exposed to
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10 dyn/cm2 fluid shear stress in the orbital shaker (OS) systems for the indicated time and analysed
for phosphorylated and total PKA levels by Western blotting. MAGI silencing reduces flow-induced
sustained PKA phosphorylation. (E) HUVEC under static of flow (10 dyn/cm2, 24 h) conditions in
the presence of vehicle (DMSO) or the PKA inhibitor (H89) were analysed for NO production. H89
treatment inhibits flow induced NO. NO was measured by Nitrixyte™ staining and flow cytometry
analysis. N = 3, triplicate conditions each. MFI, mean fluorescence intensity. **, p < 0.01.
From these experiments, we conclude that MAGI1 regulates eNOS Ser1177 phosphorylation and
activity through PKA and AMPK.
3.6. Transgenic Endothelial Cell Expression of MAGI1 Induces eNOS Phosphorylation at Ser1177 and Increases
NO Production in Endothelial Cells
Next, we proceeded to collect evidence that MAGI1 activates eNOS in endothelial cells in vivo.
To this end, we first generated a transgenic mouse line harbouring human MAGI1 cDNA under the tetOS
promoter response element (ST, single transgenic, tetOS::MAGI1) and crossed with transgenic mice
expressing the tet transactivator (tTA) under the control of the endothelial cell specific VE-cadherin
promoter [39] to obtain a double transgenic line (DT, VEC:tTA::tetOS:MAGI1) with doxycycline
repressible expression of MAGI1 in endothelial cells (Figure S4A). In the absence of doxycycline mice
constitutively overexpress transgenic MAGI1 in endothelial cells, while in the presence of doxycycline
transgenic expression of MAGI1 is silenced. MAGI1 mRNA and protein expression analysis in total
lung lysates from ST and DT of control mice or mice treated for three days with doxycycline, confirmed
that transgenic (human) MAGI1 mRNA and MAGI1 protein were only expressed in DT mice in the
absence of doxycycline (Figure S4B,C). The weak protein signal visible in ST and DT+doxycycline
conditions is due to the levels of endogenous MAGI1 detected by the anti-MAGI1 antibody (Figure S4C).
To demonstrate MAGI1 expression in endothelial cells, we isolated lung microvascular endothelial
cells (LEC) from ST and DT mice and cultured them for three days in the absence or presence of
doxycycline. MAGI1 protein was expressed in DT LEC, but not in DT LEC+doxycycline or ST LEC
(Figure 5A). Increased PKA Thr197 phosphorylation was visible in LEC of DT mice without doxycycline,
consistent with data obtained in HUVEC (Figure 5A). Importantly, increased phosphorylation of eNOS
was observed in LEC from DT mice compared to LEC from ST mice (Figure 5B). To collect direct
evidence for MAGI1-induced eNOS activation in vivo, we stained lungs for phosphorylated eNOS
Ser1177. Increased total MAGI1 protein and phospho-eNOS Ser1177 staining were visible in lungs of DT
mice compared to ST (Figure 5C). Consistent with these observations, production of NO in freshly
isolated LEC was significantly increased in LEC from DT mice compared to ST mice (Figure 5D).
Taken together, these results demonstrated that transgenic expression of MAGI1 in endothelial
cells in vivo increases PKA and eNOS Ser1177 phosphorylation and enhances NO production in lung
microvascular endothelial cells.
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and PKA phosphorylation. Triplicate mice, N = 3. (B) Western blotting analysis of lung endothelial cells
isolated from ST and DT mice for phosphorylated Ser1177 eNOS (P-eNOS) and total e S (T-eNOS).
DT lung endothelial cells have elevated eNOS phosphorylation. N = 2, triplicate mice (six independent
cultures). Beta actin is shown as loading control. Relative band quantifications by densitometry of
multiple experiments are shown next to the blots. (C) Lung sections from ST and DT MAGI1 mice
were stained for MAGI1, phosphorylated Ser1177 eNOS (P-eNOS) or total eNOS (T-eNOS). Increased
P-eNOS staining (brown) is visible in DT mice. Scale bar = 50 µm. (D) Analysis of NO production
by DAF-2DA staining and fluorimetric measurement in lung endothelial cells isolated from. N = 3,
triplicate conditions each. ST, single transgenic mice; DT, double transgenic mice. * p < 0.05; ** p < 0.01;
*** p < 0.001.
4. Discussion
Tight regulation of NO production is key t man homeostatic and adaptive responses in the
vascular system. Activity of eNOS, the main NOS in endothelial cells, is regulated by several
mechanisms, including phosphorylation through AKT-dependent and -independent pathways
(Figure 6) [1,7]. The relative importance of these multiple pathways is still unclear, and in particular the
regulatory components involved in PKA-dependent phosphorylation of eNOS are not fully elucidated.
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Figure 6. Proposed model. MAGI1 localizes at cell-cell contacts with VE-Cadherin. Shear stress induces
MAGI1 expression, which promotes endothelial cell alignment to flow, KLF4 expression, Ser1177eNOS
phosphorylation and NO production. MAGI1 induced Ser1177eNOS is mainly mediated through PKA
and to a lesser extent AMPK. AKT or CAMKII, two additional kinases also reported to phosphorylate
and activate eNOS, are not involved in MAGI1-mediated Ser1177eNOS phosphorylation.
Here we report that the scaffolding protein MAGI1 contributes to PKA- and, to a lesser extent,
AMPK-dependent eNOS activation and NO production. This conclusion is based on the following
observations: i) Fluid shear stress induced MAGI1 expression in HUVEC in three independent models,
silencing of MAGI1 expression impinged on eNOS Ser1177 phosphorylation and NO production;
ii) MAGI1 overexpression in HUVEC and in endothelial cells of transgenic mice, increased PKA
phosphorylation, induced eNOS Ser1177 phosphorylation in vivo, in vitro and ex vivo, as well as NO
production in vitro and ex vivo. iii) PKA inhibition suppressed eNOS Ser1177 phosphorylation and
NO production. iv) MAGI1 also induced AMPK Thr172 phosphorylation, and its inhibition partially
reduced MAGI-induced eNOS phosphorylation.
A number of MAGI1 physiological functions and involvements in pathologies, including cancer,
have been reported, but only little is known on the putative function of MAGI1 in vascular biology.
At the cellular level, MAGI1 plays an important role in stabilizing cell-cell contacts in epithelial
cells, through tight junctions [15]. MAGI1 regulates apoptosis [40], synaptic development, plasticity
and function [41]. In endothelial cells, MAGI1 enhances VE-cadherin-mediated cell adhesion [18]
and recruits ESAM to cell contacts [42]. In addition to the modulation of PI3-K/PTEN/AKT [43],
Wnt/β-catenin [22] and IQGAP signalling [44], there is a paucity of information on intracellular
signalling events modulated by MAGI1. Our results point towards a novel function of endothelial
cell MAGI1, namely the regulation of eNOS phosphorylation and activity in response to shear stress
through the PKA and AMPK pathways. MAGI1 co-localizes at cell-cell junctions together with
VE-cadherin, a sub-cellular location where eNOS and the catalytic subunit of PKA were reported
in conjunction with the regulation of NO production [45]. How MAGI1 activates PKA is unclear
at this point. PKA is a cyclic adenosine monophosphate (cAMP)-dependent kinase and two cAMP
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molecules bind to each PKA regulatory subunit causing a conformational change activating its catalytic
subunit [46]. PKA interacts with RAPGEF2 (PDZ-GEF1) required for cAMP-dependent downstream
signalling [47]. Intriguingly, MAGI1 has been shown to interact with PDZ-GEF1 in vascular endothelial
cells where it is required for VE-Cadherin dependent Rap1 activation [47]. It is plausible that MAGI1
activates PKA through a scaffolding effect clustering RAPGEF2 and PKA at adherens junctions and
thereby facilitating cAMP-mediated PKA activation.
Further evidence for a potential contribution of MAGI1 to endothelial physiology is corroborated
by its involvement in the induction of KLF4 expression in response to flow. There are numerous
studies showing that laminar shear stress is inducing KLF4 expression through both transcriptional [48]
and epigenetic [49] regulation leading to increased eNOS synthesis and NO production. In contrast,
disturbed flow increases DNA methylation of GpC islands in the KLF4 promoter, leading to its
transcriptional suppression [49]. KLF4 modulates the progression of multiple vascular conditions by
regulating the transcription of several genes in endothelial cells, smooth muscle cells and inflammatory
cells [50]. For example, KLF4 reduces smooth muscle cell differentiation and proliferation by interacting
with the serum response factor ELK1, histone deacetylases and p53 [50] and represses vascular
inflammation by inhibiting NF-κB [51].
In view of the contribution of KLF4 in mediating responses to flow and its multiple roles in vascular
physiology and pathology, it will be essential to unravel how MAGI1 regulates KFL4 expression, and in
particular whether KLF4, in turn, may regulate MAGI1 expression. Some of the ongoing experiments
are specifically addressing this important question.
Considering the importance of NO metabolism in many cardiovascular diseases, in particular
atherosclerosis and hypertension [5,52], it will be important to assess whether endothelial MAGI1
function or dysfunction may be involved in the genesis or progression of such pathologies.
5. Conclusions
The presented study demonstrates for the first time that the scaffolding protein MAGI1 regulates
shear stress-mediated NO production through a PKA/AMPK dependent eNOS phosphorylation in
endothelial cells. These results add a previously unrecognized element to the characterization of
MAGI1 function in vascular biology and to the complex mechanisms regulating NO production in
endothelial cells.
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